- Home
- DRCT vs KPRX Comparison
DRCT vs KPRX Comparison
Compare DRCT & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- KPRX
- Stock Information
- Founded
- DRCT 2018
- KPRX 1998
- Country
- DRCT United States
- KPRX United States
- Employees
- DRCT N/A
- KPRX N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DRCT Technology
- KPRX Health Care
- Exchange
- DRCT Nasdaq
- KPRX Nasdaq
- Market Cap
- DRCT 8.8M
- KPRX 9.2M
- IPO Year
- DRCT 2022
- KPRX N/A
- Fundamental
- Price
- DRCT $0.38
- KPRX $2.57
- Analyst Decision
- DRCT Strong Buy
- KPRX Strong Buy
- Analyst Count
- DRCT 1
- KPRX 1
- Target Price
- DRCT $6.00
- KPRX $10.00
- AVG Volume (30 Days)
- DRCT 5.4M
- KPRX 48.8K
- Earning Date
- DRCT 11-06-2025
- KPRX 11-07-2025
- Dividend Yield
- DRCT N/A
- KPRX N/A
- EPS Growth
- DRCT N/A
- KPRX N/A
- EPS
- DRCT N/A
- KPRX N/A
- Revenue
- DRCT $36,459,000.00
- KPRX N/A
- Revenue This Year
- DRCT $16.81
- KPRX N/A
- Revenue Next Year
- DRCT $35.28
- KPRX N/A
- P/E Ratio
- DRCT N/A
- KPRX N/A
- Revenue Growth
- DRCT N/A
- KPRX N/A
- 52 Week Low
- DRCT $0.28
- KPRX $2.21
- 52 Week High
- DRCT $6.59
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- DRCT 53.54
- KPRX 46.32
- Support Level
- DRCT $0.35
- KPRX $2.21
- Resistance Level
- DRCT $0.37
- KPRX $2.65
- Average True Range (ATR)
- DRCT 0.03
- KPRX 0.15
- MACD
- DRCT 0.01
- KPRX -0.01
- Stochastic Oscillator
- DRCT 66.89
- KPRX 57.63
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.